The aim of this study was to evaluate the validity of the bone density value of potential implant sites in HU obtained by a specific cone-beam computed tomography (CBCT) device. In this study, the HU values obtained using a MSCT scanner were used as the gold standard. Twenty mandibles (40 potential implant sites) were scanned using an MSCT scanner (Somatom Sensation 40) and a CBCT scanner (i-CAT). The MSCT images were evaluated using the Syngo CT Workplace software and the CBCT images, using the XoranCat software. The images were evaluated twice by three oral radiologists, at 60 day intervals. The trabecular bone density of the same area was evaluated on both images. Intraclass coefficients (ICC) were calculated to examine the agreement between the examiners and between the two periods of evaluation. The bone density and area of the ROI were compared by the Student t test and Bland-Altman analysis. ICCs were excellent. The mean HU value obtained using CBCT (418.06) was higher than that obtained using MSCT (313.13), with a statistically significant difference (p < 0.0001). In addition, Bland-Altman analysis showed that the HU measures were not equivalent. In conclusion, the bone density in HU with CBCT images obtained using the device studied proved unreliable, since it was higher than that obtained using MSCT.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1590/s1806-83242012000600011 | DOI Listing |
BMC Endocr Disord
January 2025
The First School of Clinical Medicine, Lanzhou University, No.199 Donggang West Road, Chengguan District, Lanzhou, Gansu Province, 730000, China.
Background: Thyroid hormone plays an important role in accumulating bone development and regulating bone metabolism. It is established that hypothyroidism is linked to increased risk of osteoporosis and fracture. However, the effects of levothyroxine (LT4) treatment on bone for hypothyroid patients remain controversial.
View Article and Find Full Text PDFRev Invest Clin
January 2025
Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, University Sains Malaysia, Penang, Malaysia.
Background: Limited information exists regarding the pathophysiological interactions between osteoporosis and chronic obstructive pulmonary disease (COPD). Objective: To study the association of Osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-Β ligand (RANKL) in male COPD patients. Methods: An observational clinical study was conducted at Penang General Hospital in Malaysia.
View Article and Find Full Text PDFMedicine (Baltimore)
November 2024
Department of Endocrinology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, P. R. China.
Studies have shown that gut microbiota (GM) and its metabolites, short-chain fatty acids (SCFAs), are associated with the development of postmenopausal osteoporosis (PMO). This study explored the clinical and laboratory evidence of the relationship of GM and SCFAs to PMO and attempted to determine the potential mechanism of action. 18 patients (Collected from the First Affiliated Hospital of Guangdong Pharmaceutical University between January 2021 and August 2021) were included in this retrospective study, including 10 PMO women and 8 healthy young women as the healthy control (HC) group from Guangzhou, China.
View Article and Find Full Text PDFJ Bone Miner Res
January 2025
Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Bone mineral density (BMD), an important marker of bone health, is regulated by a complex interaction of proteins. Plasma proteomic analyses can contribute to identification of proteins associated with changes in BMD. This may be especially informative in stages of bone accrual and peak BMD achievement (i.
View Article and Find Full Text PDFImportance: Fragility fractures result in significant morbidity.
Objective: To review evidence on osteoporosis screening to inform the US Preventive Services Task Force.
Data Sources: PubMed, Embase, Cochrane Library, and trial registries through January 9, 2024; references, experts, and literature surveillance through July 31, 2024.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!